Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 7/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24388763 | 1.00 | PTPN11 (0.40) | PTPN11HTR2AHTR2CHTR2BALPL | |
| SCHEMBL21845273 | 0.83 | PTPN11 (0.40) | PTPN11HTR2AHTR2CHTR2BALPL | |
| SCHEMBL21887237 | 0.83 | PTPN11 (0.40) | PTPN11HTR2AHTR2CHTR2BALPL | |
| SCHEMBL21887334 | 0.83 | PTPN11 (0.40) | PTPN11HTR2AHTR2CHTR2BALPL | |
| SCHEMBL21887329 | 0.83 | PTPN11 (0.40) | PTPN11HTR2AHTR2CHTR2BALPL | |
| SCHEMBL24389194 | 0.83 | PTPN11 (0.38) | PTPN11ALPLPDE10AGRM4 | |
| SCHEMBL24389199 | 0.83 | PTPN11 (0.38) | PTPN11ALPLPDE10AGRM4 | |
| SCHEMBL21807519 | 0.83 | PTPN11 (0.38) | PTPN11ALPLPDE10AGRM4 | |
| SCHEMBL24389059 | 0.83 | PTPN11 (0.38) | PTPN11ALPLPDE10AGRM4 | |
| SCHEMBL31144797 | 0.83 | PTPN11 (0.38) | PTPN11ALPLPDE10AGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167134-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20210380604-A1 | TRI-SUBSTITUTED HETEROARYL DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2021-12-09 | — | — | US | disclosed |
| US-20210188876-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-11034705-B2 | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210040122-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2021-02-11 | — | — | US | disclosed |
| US-10894797-B2 | Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-20200277308-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2020-09-03 | — | — | US | disclosed |
| US-20200115389-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277308-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | SRC, PTPRCAP, PTPRC | PTPN11 27/4885HTR2A 3038/4885HTR2C 2787/4885 |
| US-20230167134-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | SRC, PTPRCAP, PTPRC | PTPN11 32/4885HTR2A 3073/4885HTR2C 2886/4885 |
| US-10894797-B2 | Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors | SRC, PTPRCAP, PTPRC | PTPN11 27/4885HTR2A 3038/4885HTR2C 2787/4885 |
| US-11034705-B2 | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors | SRC, PTPRCAP, PTPRC | PTPN11 32/4885HTR2A 3073/4885HTR2C 2886/4885 |
| US-20200115389-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | SRC, PTPRCAP, PTPRC | PTPN11 27/4885HTR2A 3038/4885HTR2C 2787/4885 |
| US-20210380604-A1 | TRI-SUBSTITUTED HETEROARYL DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | SRC, PTPRCAP, PTPN2 | PTPN11 29/4885HTR2A 2585/4885HTR2C 2714/4885 |
| US-20210188876-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | SRC, PTPRCAP, PTPRC | PTPN11 32/4885HTR2A 3073/4885HTR2C 2886/4885 |
| US-20210040122-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | SRC, PTPRCAP, PTPRC | PTPN11 32/4885HTR2A 3073/4885HTR2C 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.